Institute of Primary and Community Care, Schwanenplatz 7, 6004, Luzern, Switzerland.
santé24, Palmstrasse 26b, 8401, Winterthur, Switzerland.
BMC Health Serv Res. 2020 Nov 27;20(1):1097. doi: 10.1186/s12913-020-05956-2.
There is consensus that vitamin D supplementation is often indicated but population-based screening by laboratory testing for vitamin D deficiency is inadequate. Testing should be restricted to people at high risk of severe deficiency. This study describes the current lab testing for vitamin D deficiency in the adult population of Switzerland.
We assessed Swiss health insurance data (SWICA) for incidence of lab testing for vitamin D levels, comparing the years 2015 and 2018. Claims were analyzed for associations between lab testing and age, sex, medical indications, insurance status and geographic location in multivariable regression analyses. We also estimated the costs of vitamin D testing.
Data from 200,043 and 200,046 persons for 2015 and 2018, respectively, were analyzed. Vitamin D level was tested in 14% of the sample population in 2015 and 20% in 2018. Testing increased by 69% for individuals aged 26-30. Testing was associated with being middle-aged to young senior citizens, female, medical indications (pregnancy, renal disease, osteoporosis, hyperparathyroidism, HIV, glucocorticoid intake), more chronic conditions, having a mandatory insurance with a low deductible, additional insurance coverage, and living in urban areas. We estimate that the total laboratory cost to mandatory insurance was about 90 million Swiss francs in 2018.
Despite recommendations for routine vitamin D supplementation, vitamin D testing of low risk individuals is common and increasing in Switzerland.
人们普遍认为维生素 D 补充剂通常是必要的,但通过实验室检测来筛查人群是否缺乏维生素 D 的做法并不充分。检测应仅限于有严重缺乏风险的人群。本研究描述了瑞士成年人中维生素 D 缺乏的当前实验室检测情况。
我们评估了瑞士健康保险数据(SWICA)中维生素 D 水平检测的发生率,并比较了 2015 年和 2018 年的数据。在多变量回归分析中,对检测与年龄、性别、医学指征、保险状况和地理位置之间的关系进行了分析。我们还估算了维生素 D 检测的费用。
分析了 2015 年和 2018 年分别有 200043 人和 200046 人的数据。2015 年和 2018 年,分别有 14%和 20%的样本人群进行了维生素 D 水平检测。26-30 岁人群的检测量增加了 69%。检测与中年至年轻的老年人群、女性、医学指征(妊娠、肾脏疾病、骨质疏松症、甲状旁腺功能亢进症、HIV、糖皮质激素摄入)、更多的慢性疾病、有低免赔额的强制性保险、额外的保险覆盖范围以及居住在城市地区有关。我们估计,2018 年强制性保险的实验室总成本约为 9000 万瑞士法郎。
尽管有常规补充维生素 D 的建议,但瑞士低风险人群的维生素 D 检测仍很常见且呈上升趋势。